Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
AssigneeAllegro Pharmaceuticals, LLC
InventorsMichael John Mackel, John Park
Life of this patent
Estimating the term…
Abstract
Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
Claims10
A method for inhibiting integrin-extracellular matrix interactions in a human or animal subject in need thereof, said method comprising the step of:
- administering to the subject an effective amount of a cyclic or linear compound comprising either
- i) a peptide which comprises Glycinyl-Arginyl-GlycinylCysteic-Threonyl-Proline-COOH or
- ii) a peptide which has the formula:
- X1—R-G-Cysteic Acid-X
- where X and x1 are selected from:
- Phe-Val-Ala, -Phe-Leu-Ala, -Phe-Val-Gly, -Phe-Leu-Gly, -Phe-Pro-Gly, -Phe-Pro-Ala, -Phe-Val;
- or fromAru, Gly, Cysteic, Phe, Ala, Lea, Pro, Thr and salts thereof and any combinations of D-isomers and L-isomers thereof.
Dependencies are inferred from the claim text.